Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
fda
7
×
life sciences
national blog main
national top stories
new york top stories
7
×
boston blog main
new york blog main
boston top stories
clinical trials
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
boston
drugs
national
akcea therapeutics
alnylam pharmaceuticals
biotech
boulder/denver blog main
boulder/denver top stories
cancer
detroit blog main
detroit top stories
europe top stories
hereditary transthyretin amyloidosis
indiana blog main
indiana top stories
inotersen
onpattro
patisiran
pfizer
raleigh-durham blog main
raleigh-durham top stories
roche
seattle blog main
seattle top stories
tafamidis
texas blog main
texas top stories
What
drug
7
×
medicine
7
×
fda
approved
new
alnylam
cancer
making
oks
patients
post
rnai
specifically
afternoon
alnylam’s
announced
approves
atrophy
backs
bets
brexanolone
cells
click
daily
deeper
depression
devastating
digital
disorder
dna
eisai
ema
employ
europe
evrysdi
example
fast
field
fingerprint
flags
Language
unset
Current search:
fda
×
drug
×
medicine
×
" new york top stories "
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
5 years ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Sanofi Backs Click Therapeutics as Digital Medicines Gain Momentum